Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,245 JPY | 0.00% |
|
+2.37% | +5.02% |
10/06 | Kissei Pharmaceutical Licenses Linzagolix to JW Pharmaceutical for Korean Market | MT |
10/06 | Kissei Pharmaceutical Co., Ltd. Enters into License Agreement with Jw Pharmaceutical Corporation | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.02% | 89Cr | |
+14.98% | 914.1Cr | |
-23.31% | 433.23Cr | |
+15.70% | 427.89Cr | |
+32.83% | 415.25Cr | |
+10.56% | 219.31Cr | |
+9.30% | 197.5Cr | |
-33.37% | 197.84Cr | |
-0.50% | 164.41Cr | |
-46.20% | 167.89Cr |
- Stock Market
- Equities
- 4547 Stock
- News Kissei Pharmaceutical Co., Ltd.
- Kissei Pharmaceutical Withdraws Marketing Approval Application for Rovatirelin